Evaluation of clinical and biological prognostic factors in relapsed or refractory diffuse large B-cell lymphoma patients after previous treatment with rituximab and chemotherapy: Results of the PRO-R-IPI study

  1. Panizo, C.
  2. Rodríguez, A.J.
  3. Gutiérrez, G.
  4. Díaz, F.J.
  5. González-Barca, E.
  6. De Oña, R.
  7. Grande, C.
  8. Sancho, J.M.
  9. García-Álvarez, M.F.
  10. Sánchez-González, B.
  11. Peñalver, F.J.
  12. Cannata, J.
  13. Espeso, M.
  14. Requena, M.J.
  15. Gardella, S.
  16. Durán, S.
  17. González, A.P.
  18. Alfonso, A.
  19. Caballero, M.D.
Aldizkaria:
Clinical Lymphoma, Myeloma and Leukemia

ISSN: 2152-2669 2152-2650

Argitalpen urtea: 2015

Alea: 15

Zenbakia: 7

Orrialdeak: 398-403

Mota: Artikulua

DOI: 10.1016/J.CLML.2015.02.029 GOOGLE SCHOLAR

Garapen Iraunkorreko Helburuak